THE SOLUTION
Rose Bengal Photodynamic Antimicrobial Therapy (RB PDAT)
RB PDAT was developed at the Ophthalmic Biophysics Center of Bascom Palmer Eye Institute over more than 10 years
- Innovative therapy for acute treatment, leveraging the inherent anti-pathogenic properties of bioactive synthetic small molecule Rose Bengal (RB) and light activation
- Clinically validated by medical centers in the U.S., India, Brazil, and Mexico in hundreds of patients to date
- Non-clinical research and clinical use data published and presented in dozens of peer-reviewed journals and medical conferences by Bascom Palmer and others
Broad-Spectrum Efficacy
Active against multiple types and strains of pathogens, reducing or eliminating the likelihood of resistance
Non-Invasive Treatment
Easy to administer; avoids the need for surgery
Rapid Resolution
Faster, better treatment outcomes compared to traditional therapies
A Steadily Worsening and Very Troubling Global Health Risk to Sight
Poor eye hygiene, environmental causative elements, limitations of and inaccessibility to standard medicines, and increasing multidrug resistance are among the risk factors that contribute to these rising numbers
5-10 million
People affected annually
by infectious keratitis, globally
100,000
Americans affected annually
by infectious karatitis
Pathogenic Sources
Bacterial, Fungal, Viral, and Parasitic
Clinically Validated Treatment:
Rose Bengal PDAT
Potentially safe, effective, durable, non-invasive, accessible, affordable therapy that can treat broad-spectrum eye infections, address multidrug resistant pathogens, achieve timely complete resolution, and avoid surgical intervention
- Topical application and illumination of bioactive synthetic small molecule rose bengal
- Demonstrated broad-spectrum activity both in vitro and in clinical use
- No significant toxicity/adverse effects in keratocytes, corneal structures, or the iris or the retina
Multi-modal mechanisms of action:
- RB-generated reactive oxygen species damages microbial cells (cell membranes, proteins, DNA) and leads to their death
- Emerging RB may induce anti-microbial peptides in eye epithelial cells upon contact, leading to pro- and anti-inflammatory modulation of innate and adaptive immune responses and signaling pathways
Simulation of RB PDAT Treatment
Global RB PDAT Clinical Data
for Infectious Keratitis
- 76% successful treatment
- Average of 184 days to clinical resolution
- Acanthamoeba, pseudomonas, fusarium
- Main risk factor: Contact lens wear
- Improved visual outcomes
- Multidrug-resistant (MDR) P aeruginosa keratitis after an artificial tear contamination outbreak
- RB PDAT has “…broad coverage and no known antibiotic resistance”
- 62% successful treatment
- Average of 45 days to clinical resolution
- Fusarium, P aeruginosa, staphylococcus epidermidis
- Main risk factors: Contact lens wear, ocular trauma, contact with soil
- 100% successful treatment of fusarium (3 patients)
- Average of 39 days to clinical resolution
- Worsened with aspergillus and acremonium (4 patients)
- Main risk factor: Contact with environment
- 73% successful treatment
- Average of 29 days to clinical resolution
- Acanthamoeba, yeast fungi, filamentous fungi, S pneumoniae, P aeruginosa
- Main risk factors: Contact lens wear, ocular trauma, contact with soil
- RB PDAT “…will improve best spectacle corrected visual acuity and also reduce complications such as corneal perforation and the need for therapeutic penetrating keratoplasty”
- Topical antimicrobial + RB PDAT vs. Top. antimicrobial + sham RB PDAT (1:1)